Insulet PODD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept podd:CashCashEquivalentsAndRestrictedCashCurrent.
The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Insulet's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Insulet's cash & equivalents?
- Insulet (PODD) reported cash & equivalents of $480.4M in Q1 2026.
- How has Insulet's cash & equivalents changed year-over-year?
- Insulet's cash & equivalents decreased by 62.6% year-over-year, from $1.28B to $480.4M.
- What is the long-term trend for Insulet's cash & equivalents?
- Over 5 years (2020 to 2025), Insulet's cash & equivalents has grown at a -4.6% compound annual growth rate (CAGR), from $907.2M to $716.1M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and potential for investment, while a decrease may indicate high cash burn or significant capital deployment.
- How does cash & equivalents compare across companies?
- Peers in the medical device sector typically maintain high cash balances to support long-term R&D cycles and potential M&A activity.